MBX Biosciences, Inc.
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 14.66M | 12.84M | 10.98M | 9.86M | 8.86M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 86.56M | 81.41M | 68.19M | 59.58M | 50.91M |
| Operating Income | -86.56M | -81.41M | -68.19M | -59.58M | -50.91M |
| Income Before Tax | -77.02M | -73.47M | -61.92M | -55.18M | -47.20M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -77.02 | -73.47 | -61.92 | -55.18 | -47.20 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -77.02M | -73.47M | -61.92M | -55.18M | -47.20M |
| EBIT | -86.56M | -81.41M | -68.19M | -59.58M | -50.91M |
| EBITDA | -86.29M | -81.14M | -67.95M | -59.35M | -50.72M |
| EPS Basic | -4.55 | -16.59 | -26.13 | -33.39 | -40.00 |
| Normalized Basic EPS | -2.90 | -10.42 | -16.39 | -21.44 | -25.57 |
| EPS Diluted | -4.55 | -16.59 | -26.13 | -33.39 | -40.00 |
| Normalized Diluted EPS | -2.90 | -10.42 | -16.39 | -21.44 | -25.57 |
| Average Basic Shares Outstanding | 106.77M | 74.58M | 42.37M | 10.12M | 4.68M |
| Average Diluted Shares Outstanding | 106.77M | 74.58M | 42.37M | 10.12M | 4.68M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |